Synthetic Biologics, Inc. (NYSEMKT:SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, reported that the University of California, Los Angeles (UCLA) School of Medicine announced preliminary, positive topline data from the Phase II clinical trial evaluating Trimesta™ (oral estriol), the Company’s oral, once-daily treatment for relapsing-remitting multiple sclerosis (RRMS) in women.Synthetic Biologics Inc (NYSEMKT:SYN) shares after opening at $2.93 moved to $3.03 on last trade day and at the end of the day closed at $2.10. Company price to cash ratio in past twelve months was calculated as 8.38. Synthetic Biologics Inc (NYSEMKT:SYN) showed a negative weekly performance of -29.29%.
Prothena Corporation plc (NASDAQ:PRTA) a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced that an abstract was published by the XIV International Symposium on Amyloidosis (ISA) and described interim data from an ongoing Phase 1 study of NEOD001, a monoclonal antibody in clinical development for the treatment of patients with AL amyloidosis and persistent organ dysfunction, as of the abstract submission date. Prothena Corporation PLC (NASDAQ:PRTA) shares fell -30.68 % in last trading session and ended the day on $26.12. PRTA return on equity ratio is recorded as -33.10% and its return on assets is -30.90%. Prothena Corporation PLC (NASDAQ:PRTA) yearly performance is 212.81%.
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) announced that management will host a conference call on Tuesday, May 6, 2014 at 4:30 p.m. EDT to review the Company’s third quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results on the same day, prior to the conference call. Biota Pharmaceuticals Inc (NASDAQ:BOTA) shares moved down -33.93% in last trading session and was closed at $3.68 while trading in range of $3.50 – $4.43 – Biota Pharmaceuticals Inc (NASDAQ:BOTA) year to date (YTD) performance is -12.17%.
RXi Pharmaceuticals Corporation (NASDAQ:RXII) a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced that the first patient has enrolled in their Phase 2a study (RXI-109-1401) with RXI-109 for the prevention of keloid recurrence. RXi Pharmaceuticals Corp (NASDAQ:RXII) weekly performance is -14.54%. On last trading day company shares ended up $3.41. RXi Pharmaceuticals Corp (NASDAQ:RXII) distance from 50-day simple moving average (SMA50) is -28.30%. Analysts mean target price for the company is $13.50.